1. Correction: Targeting DORIS Remission and LLDAS in SLE: A Review.
- Author
-
Parra Sánchez, Agner R., van Vollenhoven, Ronald F., Morand, Eric F., Bruce, Ian N., Kandane-Rathnayake, Rangi, Weiss, Gudrun, Tummala, Raj, Al-Mossawi, Hussein, and Sorrentino, Alessandro
- Subjects
INVESTIGATIONAL drugs ,IMMUNOSUPPRESSIVE agents ,SYSTEMIC lupus erythematosus ,PHYSICIANS - Abstract
This correction notice addresses minor errors in the original article titled "Targeting DORIS Remission and LLDAS in SLE: A Review." The errors pertain to the definition of DORIS remission and the data presented in Tables 1 and 3. The corrected definition of DORIS remission includes achieving a clinical SLEDAI-2K = 0 and a Physician's Global Assessment (PGA) < 0.5, irrespective of serology, with the use of antimalarials, low-dose glucocorticoids, and/or stable doses of immunosuppressants. The updated data in Table 3 shows changes in the number and percentage of patients achieving DORIS remission in the placebo group, as well as updated odds ratios and p-values for the comparison between treatment groups. The original article has been corrected. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF